Skip to main content
Project

Metabolic and chromatin reprogramming of hematopoietic stem cells (HSC) during day-night oscillations and aging

Brazil
Middle East
Project ID
109153
Total Funding
CAD 670,000.00
Project Status
Completed
End Date
Duration
36 months

Programs and partnerships

Lead institution(s)

Summary

Humans have enormous demands for blood production. Alterations in the functioning of the human blood system lie at the heart of many diseases, including cancer, infections, and auto-immune disorders. With age, human blood production changes and immune function is decreased.Read more

Humans have enormous demands for blood production. Alterations in the functioning of the human blood system lie at the heart of many diseases, including cancer, infections, and auto-immune disorders. With age, human blood production changes and immune function is decreased. There is a need to improve our understanding of how our blood system develops from the rare hematopoietic stem cells (HSC) that originate all blood cells, and how aging disrupts this process. This information is critical to develop new therapies against many diseases that originate from abnormal immune cell functioning and to potentially alleviate and/or reverse accelerated decline in HSC function.

Previous studies have shown that melatonin is critical to the day/night oscillation pattern that controls the switch HSCs make between the generation of mature blood cells and their replenishment. They also show that sphingolipids govern HSC function and the generation of mature blood cells. Melatonin and sphingolipids are therefore linked, and their levels change with age. This project will use state-of-the-art assays to study normal human blood cells as well as genetically engineered mice to investigate whether these molecules are behind the age-related decline in HSC function.

The project was selected for funding through the fifth research competition of the Joint Canada-Israel Health Research Program. This initiative is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation, and the Azrieli Foundation.

Research outputs

Access full library of outputs Opens in new tab
Article
Language:

English

Summary

Acute myeloid leukemia (AML) is a caricature of normal hematopoiesis driven from leukemia stem cells (LSC) that share some hematopoietic stem cell (HSC) programs including responsiveness to inflammatory signaling. Although inflammation dysregulates mature myeloid cells and influences stemness programs and lineage determination in HSCs by activating stress myelopoiesis, such roles in LSCs are poorly understood. Here, we show that S1PR3, a receptor for the bioactive lipid sphingosine-1-phosphate, is a central regulator that drives myeloid differentiation and activates inflammatory programs in both HSCs and LSCs. S1PR3-mediated inflammatory signatures varied in a continuum from primitive to mature myeloid states across cohorts of patients with AML, each with distinct phenotypic and clinical properties. S1PR3 was high in LSCs and blasts of mature myeloid samples with linkages to chemosensitivity, whereas S1PR3 activation in primitive samples promoted LSC differentiation leading to eradication. Our studies open new avenues for therapeutic target identification specific for each AML subset.

Author(s)
Xie, Stephanie Z.
Article
Summary

It is critical to understand how human quiescent long-term hematopoietic stem cells (LT-HSCs) sense demand from daily and stress-mediated cues and then transition into bioenergetically active progeny to differentiate and meet these cellular needs. However, the demand-adapted regulatory circuits of these early steps of hematopoiesis are largely unknown. Here we show that lysosomes, sophisticated nutrient-sensing and signaling centers, are regulated dichotomously by transcription factor EB (TFEB) and MYC to balance catabolic and anabolic processes required for activating LT-HSCs and guiding their lineage fate. TFEB-mediated induction of the endolysosomal pathway causes membrane receptor degradation, limiting LT-HSC metabolic and mitogenic activation, promoting quiescence and self-renewal, and governing erythroid-myeloid commitment. In contrast, MYC engages biosynthetic processes while repressing lysosomal catabolism, driving LT-HSC activation. Our study identifies TFEB-mediated control of lysosomal activity as a central regulatory hub for proper and coordinated stem cell fate determination.

Author(s)
Garcıa-Prat, Laura
Article
Summary

Lifelong blood production requires long-term hematopoietic stem cells (LT-HSCs), marked by stemness states involving quiescence and self-renewal, to transition into activated short-term HSCs (ST-HSCs) with reduced stemness. As few transcriptional changes underlie this transition, we used single-cell and bulk assay for transposase-accessible chromatin sequencing (ATAC-seq) on human HSCs and hematopoietic stem and progenitor cell (HSPC) subsets to uncover chromatin accessibility signatures, one including LT-HSCs (LT/HSPC signature) and another excluding LT-HSCs (activated HSPC [Act/HSPC] signature). These signatures inversely correlated during early hematopoietic commitment and differentiation. The Act/HSPC signature contains CCCTC-binding factor (CTCF) binding sites mediating 351 chromatin interactions engaged in ST-HSCs, but not LT-HSCs, enclosing multiple stemness pathway genes active in LT-HSCs and repressed in ST-HSCs. CTCF silencing derepressed stemness genes, restraining quiescent LT-HSCs from transitioning to activated ST-HSCs. Hence, 3D chromatin interactions centrally mediated by CTCF endow a gatekeeper function that governs the earliest fate transitions HSCs make by coordinating disparate stemness pathways linked to quiescence and self-renewal.

Author(s)
Takayama, Naoya
Article
Language:

English

Summary

Age-related clonal hematopoiesis is a major risk factor for myeloid malignancy and myeloid skewing is a hallmark of aging. However, while it is known that non-cell-autonomous components of the microenvironment can also influence this risk, there have been few studies of how the spatial architecture of human bone marrow (BM) changes with aging. Here, we show that BM adiposity increases with age, which correlates with increased density of maturing myeloid cells and CD34+ hematopoietic stem/progenitor cells (HSPCs) and an increased proportion of HSPCs adjacent to adipocytes. However, NGFR+ bone marrow stromal cell (NGFR+ BMSC) density and distance to HSPCs and vessels remained stable. Interestingly, we found that, upon aging, maturing myeloid cell density increases in hematopoietic areas surrounding adipocytes. We propose that increased adjacency to adipocytes in the BM microenvironment may influence myeloid skewing of aging HSPCs, contributing to age-related risk of myeloid malignancies.

Author(s)
Aguilar-Navarro, Alicia G.
Access full library of outputs Opens in new tab

About the partnership

Partnership(s)

Joint Canada-Israel Health Research Program

Canada’s International Development Research Centre, in partnership with the Azrieli Foundation, the Canadian Institutes of Health Research (CIHR) and the Israel Science Foundation (ISF), is supporting cutting-edge biomedical and global health research.

Share this page